
LVTX Stock Forecast & Price Target
LVTX Analyst Ratings
Bulls say
LAVA Therapeutics NV is actively advancing its immuno-oncology pipeline, with a focus on bispecific antibody development using the Gammabody platform, which positions the company to potentially address significant unmet needs in cancer treatment. The recent agreement with XOMA Royalty for an acquisition at a cash price between $1.16 and $1.24 per share reinforces the company's financial stability and strategic growth direction. Additionally, the presence of multiple promising pipeline products such as LAVA-1266 and LAVA-1427 suggests a robust potential for future value creation, indicating a positive long-term outlook for the company's stock.
Bears say
LAVA Therapeutics is facing a negative outlook due to the decision to discontinue its Phase 1 study of LAVA-1266, which suggests significant setbacks in its clinical development pipeline. Additionally, the company's recent acquisition activities have led to a reduction in the price target from $1.50 to $1.24 per share, indicating a reassessment of its financial position and future prospects. The overall shift in strategy and project wind-down may contribute to investor concerns regarding the viability of its remaining pipeline candidates.
This aggregate rating is based on analysts' research of LAVA Therapeutics NV and is not a guaranteed prediction by Public.com or investment advice.
LVTX Analyst Forecast & Price Prediction
Start investing in LVTX
Order type
Buy in
Order amount
Est. shares
0 shares